

Alcohol interventions in secondary and further education

NICE guideline: methods

NICE guideline <number>

Methods

February 2019

Draft for Consultation

*Evidence reviews were developed by
Public Health Internal Guideline
Development team*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

ISBN:

Contents

Development of the guideline.....	5
What this guideline covers.....	5
What this guideline does not cover.....	5
Methods	6
Developing the review questions and outcomes.....	6
Reviewing research evidence.....	6
Data synthesis for intervention studies	7
Data synthesis for qualitative reviews.....	7
Appraising the quality of evidence	8
Intervention studies	8
Qualitative evidence	8
GRADE for interventional evidence	8
Presenting the evidence	9
Reviewing economic evidence	10
Appraising the quality of economic evidence	10
Health economic modelling.....	10
Resource impact assessment.....	11

1 **Development of the guideline**

2 **What this guideline covers**

3 This guideline covers the prevention and reduction of alcohol use through school-
4 based interventions in secondary and further education. It looks at primary prevention
5 through universal education as well as secondary prevention through targeted
6 interventions delivered in schools for children and young people aged 11 to 18 and
7 young people aged 18 to 25 with special educational needs and disabilities (SEND).

8 **What this guideline does not cover**

9 The guide does not cover interventions for children under the age of 11, children who
10 are home-schooled, prevention interventions in the community or areas covered by
11 other NICE guidance such as referral and treatment for alcohol misuse.

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 **Methods**

2 This guideline was developed in accordance with the process set out in ‘Developing
3 NICE guidelines: the manual (2014)’. A booklet, ‘How NICE guidelines are
4 developed: an overview for stakeholders, the public and the NHS’ is available. In
5 instances where the guidelines manual does not provide advice, additional methods
6 are described below.

7 Declarations of interest were recorded according to the 2018 NICE conflicts of
8 interest policy.

9 **Developing the review questions and outcomes**

10 This is an update of a previous guideline. The 4 review questions developed for this
11 guideline were based on the key areas identified in the guideline [scope](#). The key
12 areas have changed since the previous guideline in that the scope no longer covers
13 children under the age of 11 and now includes those with SEND aged 18-25 (in line
14 with Children and Families Act 2014). Review questions to cover these key areas
15 were drafted by the NICE Public Health Internal Guideline Development team, and
16 refined and validated by the guideline committee.

17 The review questions were based on the following frameworks:

- 18 • population, intervention, comparator and outcome (PICO) for reviews of
19 interventions

20 Full literature searches, evidence tables including critical appraisal for all included
21 studies, tables of excluded studies with reasons for exclusion and evidence reviews
22 were completed for all review questions.

23 **Reviewing research evidence**

24 The identification of evidence for evidence review in the guideline was conformed to
25 the methods set out in chapter 5 of the “Developing NICE Guidelines: the manual”
26 (2014). The purpose of the search was to identify the best available evidence to
27 address review questions without producing an unmanageable volume of results.

28 Relevant databases and websites, (see [Search strategies](#)) were searched
29 systematically to identify effectiveness, cost effectiveness and qualitative research
30 evidence. The principal database search strategy is listed in [Search strategies](#). The
31 principal strategy has been developed in MEDLINE (Ovid interface) and was be
32 adapted, as appropriate, for use in the other sources listed in [Search strategies](#)
33 taking into account their size, search functionality and subject coverage. As this was
34 an update of existing guidance, evidence relevant to the new protocols from the
35 previous guideline was brought forward for assessment. To identify evidence
36 published since 2006, the searches were limited from 2006 onwards. The committee
37 decided that there was no need to search further back for studies on the new key
38 area focusing on the SEND population because only studies published since the
39 Children and Families Act 2014 would be relevant.

40 Randomised controlled trials were included if they evaluated interventions related to
41 each specific review question. Systematic reviews of intervention studies were used

1 as a source for primary studies. Qualitative studies were included wherever exploring
2 views and/or experiences children and young people, their parents/carers and people
3 delivering alcohol interventions regarding the acceptability of the interventions.

4 Papers were excluded if they:

- 5 • were not published in the English language or were not carried out in OECD
6 countries
- 7 • were only available as abstracts, conference proceedings, guideline/health
8 technology assessment reports
- 9 • were published before the year 1990^a

10 Data synthesis for intervention studies

- 11 1. The identified studies were considered heterogeneous and it was decided it
12 would not be appropriate to conduct a meta-analysis. Therefore, the study
13 results were presented individually in GRADE using the following process:
14 Where individual RCTs reported an OR/RR or MD and 95% confidence
15 intervals, this data was extracted and assessed in GRADE.
- 16 2. Where individual RCTs did not report an OR/RR or MD:
 - 17 a. the RR 95% CI was calculated using an excel calculator and
 - 18 b. the MD 95% CI was calculated using an [online calculator](#).
- 19 3. Where cluster RCTs have statistically adjusted for the effects of clustering
20 and have reported the adjusted OR/RR or MD and 95% confidence intervals,
21 this data was extracted and assessed in GRADE.
- 22 4. Where cluster RCTs have not reported the adjusted OR/RR or MD but have
23 reported raw data, the effective sample sizes were calculated using an intra-
24 class correlation coefficient (ICC) (as described in chapter 16.3 of the
25 Cochrane Handbook for Systematic Reviews of Interventions (2011). The
26 ICC, if the data allowed, was taken from either:
 - 27 a. The study where reported
 - 28 b. The mean ICC from other studies reporting on the same outcome.
 - 29 c. An ICC reported in another single study on a similar outcome.
 - 30 d. The mean ICC of other studies in a similar outcome.
- 31 5. The effective sample sizes were then used to calculate an RR or MD using
32 the calculators in steps 1 and 2.
- 33 6. All calculated RRs 95% CI and MDs 95% CI were assessed in GRADE.

34 For studies that did not report the data to allow for the steps above, for example,
35 studies that did not report the number of people in each arm, were reported as in the
36 paper and assessed in GRADE.

37 Studies that did not report raw data were not assessed in GRADE but were
38 summarised in evidence statements.

39 Data synthesis for qualitative reviews

40 Where multiple qualitative studies were identified for a review question, information
41 from these studies was summarise using a thematic synthesis. By examining the
42 findings of each included study, descriptive themes were independently identified and
43 coded. Once all of the included studies had been examined and coded, the resulting

a This was the cut-off date specified in the previous guideline

1 themes and sub-themes were evaluated to examine their relevance to the review
 2 questions, the importance given to each theme, and the extent to which each theme
 3 recurred across the different studies. The qualitative synthesis then proceeded by
 4 using these 'descriptive themes' to develop 'analytical themes', which were
 5 interpreted by the reviewer in light of the overarching review questions.

6 Appraising the quality of evidence

7 Intervention studies

8 Quality assessment for all included RCTs was conducted using the Cochrane Risk of
 9 Bias 2 tool (2016) for individual RCTs and cluster RCTs. The quality of each
 10 individual study was assessed at outcome level using this tool.

11 The quality was interpreted as follows:

- 12 • Low risk of bias – The true effect size for the study is likely to be close to the
 13 estimated effect size.
- 14 • Some concerns – There is a possibility the true effect size for the study is
 15 substantially different to the estimated effect size.
- 16 • High risk of bias – It is likely the true effect size for the study is substantially
 17 different to the estimated effect size.

18 Qualitative evidence

19 Individual qualitative studies were quality assessed using the CASP qualitative
 20 checklist. Each individual study was classified into one of the following three groups:

- 21 • Low risk of bias – The findings and themes identified in the study are likely to
 22 accurately capture the true picture.
- 23 • Moderate risk of bias – There is a possibility the findings and themes identified in
 24 the study are not a complete representation of the true picture.
- 25 • High risk of bias – It is likely the findings and themes identified in the study are not
 26 a complete representation of the true picture

27 GRADE for interventional evidence

28 GRADE was used to assess the quality of evidence for the selected outcomes as
 29 specified in 'Developing NICE guidelines: the manual (2014)'. Data from all RCT's
 30 were initially rated as high quality and the quality of the evidence for each outcome
 31 was downgraded or not from this initial point, based on the criteria given in Table 1

32 **Table 1: GRADE**

GRADE criteria	Reasons for downgrading or not downgrading confidence
Risk of bias	Randomised controlled studies and cluster randomised controlled studies The certainty of the evidence was downgraded if there were concerns about the design or execution of the study, including concealment of allocation, blinding, loss to follow up using the Cochrane Risk of Bias 2 tool for individually randomised controlled trials and cluster randomised controlled trials (2016); For example, limitations in the study design and

GRADE criteria	Reasons for downgrading or not downgrading confidence
	implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question. The certainty of the evidence was downgraded if there were concerns about the population, intervention and outcome in the included studies and how directly these variables could address the specific review question.
Inconsistency	Because the data was not pooled, it was not possible to measure inconsistency as only single studies were used.
Imprecision	Because the data was not pooled, imprecision was measured using the line of no effect. If a 95% CI crossed the line of no effect, the certainty of the evidence was downgraded by one for imprecision.
Other issues	None

1 **Table 2: GRADE CERQual**

CERQual criteria	Reasons for downgrading or not downgrading confidence
Methodological limitations	The certainty of the evidence was downgraded if there were concerns about the design or execution of the study including whether the research design and methods of data collection were appropriate to address the aims of the research, researcher reflexivity, ethical consideration and the clarity of findings.
Coherence	Assesses whether the review finding reflects the data from primary studies. The certainty of the evidence was downgraded if some of the data contradicts the review finding.
Adequacy	Assesses the degree of richness and the amount of data to support the review finding. The certainty of the evidence was downgraded if the data was not sufficiently rich or the number of studies of participant numbers were small.
Relevance	Assesses the extent to which the data from the primary studies supporting the review finding is applicable to its context. The certainty of the evidence was downgraded if the data available was not applicable to the review question.

2 Presenting the evidence

3 As there was heterogeneity with respect to participants and interventions the
4 evidence reviews were presented to the Public Health Advisory Committee (PHAC)
5 in forest plots annotated with study characteristics and in tabular form to allow the
6 PHAC interpret the findings of the studies included in each review. Evidence was
7 reported in the reviews as described previously.

1 **Reviewing economic evidence**

2 The PHAC is required to make decisions based on the best available evidence of
3 both general effectiveness and cost-effectiveness. Guideline recommendations
4 should be based on the expected costs of the different options in relation to their
5 expected benefits (that is, their 'cost-effectiveness') rather than the total
6 implementation cost. Thus, if the evidence suggests that a strategy provides
7 significant benefits at an acceptable cost per person treated, it should be
8 recommended.

9 In order to assess the cost effectiveness of the key issues addressed in this
10 guideline, the following actions were carried out:

- 11 • A systematic review of economic evidence in the literature was conducted,
12 alongside the review of evidence on general effectiveness (see Reviewing
13 research evidence)
- 14 • A de novo economic model was developed, in order to provide cost effectiveness
15 evidence for a number of review questions

16 **Literature review**

17 The systematic reviewer:

- 18 • Identified potentially relevant studies for each review question from the economic
19 search results by reviewing titles and abstracts. Full papers were then obtained.
- 20 • Reviewed full papers against pre-specified inclusion and exclusion criteria to
21 identify relevant studies.
- 22 • Extracted key information about the studies' methods and results into evidence
23 tables (included in the relevant chapter for each review question)
- 24 • Generated summaries of the evidence in NICE economic evidence profiles
25 (included in the relevant chapter for each review question)

26 **Appraising the quality of economic evidence**

27 Studies that met the eligibility criteria were assessed using the quality appraisal
28 criteria as outlined in [Developing NICE guidelines \(NICE 2014\)](#).

29 **Health economic modelling**

30 As well as reviewing the published economic literature for each review question, as
31 described above, a de novo economic analysis was undertaken for relevant research
32 questions. The following general principles were adhered to in developing the
33 analysis:

- 34 • Methods were consistent with the NICE reference case.
- 35 • The committee was involved in the design of the model, selection of inputs
36 and interpretation of the results.
- 37 • Where possible, model inputs were based on the systematic review of the
38 clinical literature, supplemented with other published data sources identified
39 by the committee as required.

- 1 • When published data were not available committee expert opinion was used
2 to populate the model.
- 3 • Model inputs and assumptions were reported fully and transparently.
- 4 • The results were subject to sensitivity analysis and limitations were
5 discussed.
- 6 Full methods for the de-novo modelling can be found in the Alcohol HE report.

7 **Resource impact assessment**

- 8 The resource impact team used the methods outlined in the [Assessing resource](#)
9 [impact process manual](#): guidelines.
- 10 The resource impact team worked with the guideline committee from an early stage
11 to identify recommendations that either individually or cumulatively have a substantial
12 impact on resources. The aim was to ensure that a recommendation does not
13 introduce a cost pressure into the health and social care system unless the
14 committee is convinced of the benefits and cost effectiveness of the
15 recommendation. The team gave advice to the committee on issues related to the
16 workforce, capacity and demand, training, facilities and educational implications of
17 the recommendations.